Reglan Tardive Dyskinesia Settlement: Criteria Explained

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

What are the criteria for a Reglan tardive dyskinesia settlement

Settlement criteria typically require evidence of tardive dyskinesia diagnosis after Reglan use, medical records confirming the condition, and proof that Reglan was prescribed for longer than 12 weeks. Each case is evaluated individually. Consult a qualified attorney for specific legal guidance.

From General Health Surveillance to Specific Drug Risks

The legacy of general health and science information has long provided a foundation for public understanding of wellness, disease prevention, and medical surveillance. This heritage emphasizes continuous data collection, evaluation of target populations, and timely dissemination of findings to improve health outcomes. Within this broad context, discussions have historically focused on lifestyle factors, such as diet and physical activity, as well as occupational health monitoring. As the field evolved, attention increasingly turned to the long-term effects of pharmaceutical interventions and the importance of monitoring adverse outcomes in specific populations. This shift naturally leads to a more focused concern: the occupational exposure to medications and their potential consequences. In particular, the widespread use of Reglan (metoclopramide) in clinical settings has raised questions about the risk of tardive dyskinesia among patients who have been exposed to the drug over extended periods. Understanding the criteria for settlement in cases of Reglan-related tardive dyskinesia requires a careful examination of exposure history, duration of use, and the emergence of movement disorders. This transition from general health information to a specific occupational exposure concern underscores the need for precise documentation and evaluation in both clinical and legal contexts.

Clinical Presentation and Pharmacological Link of Tardive Dyskinesia

Tardive dyskinesia (TD) is characterized by involuntary, repetitive movements, often of the face or tongue, and sometimes involving the trunk or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). These movements can be disfiguring and may persist after Reglan is discontinued. The condition is caused by exposure to dopamine receptor blocking agents, including metoclopramide, and while initially associated with typical antipsychotics, the incidence is likely similar with antiemetics such as Reglan (https://pubmed.ncbi.nlm.nih.gov/29433808/). Increased prescribing of these agents and low rates of remission have contributed to a rising prevalence of TD (https://pubmed.ncbi.nlm.nih.gov/29433808/). The pharmacological mechanism linking Reglan to TD involves its action as a dopamine receptor antagonist. Chronic blockade of dopamine receptors in the brain's basal ganglia is thought to lead to compensatory supersensitivity, which manifests as involuntary movements. The risk of developing TD increases with the duration of Reglan treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with diabetic gastroparesis, the total duration of treatment should not exceed 12 weeks; if longer use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Similarly, for symptomatic gastroesophageal reflux, the maximum treatment duration is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Adequacy of Warnings and Risk Factors

The adequacy of warnings regarding Reglan and TD is a critical risk consideration. The prescribing information includes a boxed warning stating that metoclopramide can cause TD, a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The warning emphasizes using Reglan for the shortest duration necessary and periodically reassessing the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Additionally, Reglan should be immediately discontinued if signs or symptoms of TD develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, some patients may have been exposed to Reglan for extended periods without adequate monitoring, potentially due to off-label use or lack of adherence to prescribing guidelines. Data suggest that the risk of TD from metoclopramide is low, in the range of 0.1% per 1000 patient years, which is far below previously estimated risks of 1%-10% suggested in treatment guidelines (https://pubmed.ncbi.nlm.nih.gov/31050085/). High-risk groups include elderly females, diabetics, patients with liver or kidney failure, and those on concomitant antipsychotic drug therapy, which reduces the threshold for neurological complications (https://pubmed.ncbi.nlm.nih.gov/31050085/).

Settlement Considerations and Legal Context

Settlement-related considerations for affected patients often hinge on the timeline between Reglan exposure and documented harm. The risk of TD is dose- and duration-dependent, with longer exposure increasing the likelihood of developing the condition (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients who develop TD, the condition may be irreversible, and treatment options include VMAT2 inhibitors such as tetrabenazine, which have been FDA approved for TD (https://pubmed.ncbi.nlm.nih.gov/29433808/). In the context of settlements, patients must demonstrate that their TD was caused by Reglan exposure and that the manufacturer failed to provide adequate warnings. The boxed warning and precautions in the prescribing information are central to this argument. The warning states that metoclopramide can cause TD and that the risk increases with duration and dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, if a patient was prescribed Reglan for longer than 12 weeks without monitoring, or if they were not informed of the risk, this may support a claim. The timeline between exposure and harm is also important; TD typically develops after months or years of treatment, but it can occur sooner in high-risk individuals. Overall, the evidence underscores the importance of adhering to prescribing guidelines for Reglan to minimize the risk of TD. For patients who have developed TD, settlement considerations depend on the adequacy of warnings, the duration of exposure, and the presence of risk factors. The boxed warning provides clear guidance on limiting treatment duration and monitoring for symptoms, but deviations from these recommendations may form the basis for legal claims.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is tardive dyskinesia and how is it linked to Reglan?

Tardive dyskinesia (TD) is a potentially irreversible movement disorder characterized by involuntary, repetitive movements, often of the face or tongue. It is caused by exposure to dopamine receptor blocking agents like Reglan (metoclopramide). The risk increases with longer treatment duration and higher cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

What are the settlement criteria for Reglan-related tardive dyskinesia?

Settlement criteria typically require documented Reglan exposure, a confirmed TD diagnosis, and evidence that the manufacturer failed to provide adequate warnings. Key factors include duration of use exceeding 12 weeks without monitoring, presence of risk factors (e.g., elderly, diabetic), and the timeline between exposure and onset of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

What does the boxed warning for Reglan say about tardive dyskinesia?

The boxed warning states that metoclopramide can cause tardive dyskinesia, a potentially irreversible serious movement disorder. It emphasizes using Reglan for the shortest duration necessary and discontinuing immediately if signs of TD develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.